BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Tifeglipron readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Tifeglipron\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06982131-158@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20261207
DTEND;VALUE=DATE:20261208
SUMMARY:Tifeglipron: Phase 1 readout est. (NCT06982131)
DESCRIPTION:Tifeglipron\, phase 1\, Obesity.\nStudy: A Study Investigating 
 the Safety of RO7795081 and the Effect of RO7795081 on How the Body Proces
 ses Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese
  Adult Participants\nEstimated primary completion: 7 December 2026. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/tifeglipron#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06982131
URL:https://assetmemo.bio/drug/tifeglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07499050-158@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20270109
DTEND;VALUE=DATE:20270110
SUMMARY:Tifeglipron: Phase 1 readout est. (NCT07499050)
DESCRIPTION:Tifeglipron\, phase 1\, Obesity.\nStudy: A Study of Multiple Do
 ses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Pa
 rticipants With Obesity or Overweight\nEstimated primary completion: 9 Jan
 uary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tifeglipro
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 499050
URL:https://assetmemo.bio/drug/tifeglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07741604-158@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Tifeglipron: Phase 1 readout est. (NCT07741604)
DESCRIPTION:Tifeglipron\, phase 1.\nStudy: A Study Investigating the Safety
  of RO7795081 and How the Body Processes RO7795081 in People With Normal o
 r Decreased Kidney Functions\nEstimated primary completion: 1 February 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/tifeglipron#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07741604
URL:https://assetmemo.bio/drug/tifeglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07112872-158@assetmemo.bio
DTSTAMP:20261121T005627Z
DTSTART;VALUE=DATE:20280205
DTEND;VALUE=DATE:20280206
SUMMARY:Tifeglipron: Phase 2 readout est. (NCT07112872)
DESCRIPTION:Tifeglipron\, phase 2\, Type 2 Diabetes.\nStudy: A Study to Com
 pare Different Doses of Tifeglipron (RO7795081) With Placebo or Semaglutid
 e in People With Type 2 Diabetes\nEstimated primary completion: 5 February
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/tifeglipron#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT071128
 72
URL:https://assetmemo.bio/drug/tifeglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
